In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

With an aim to enhance its service offering for particle technologies and drug product development and manufacture, Lonza has joined CMAC, an international research hub with a unique configuration of ...

Lonza will now gain access to CMAC’s network, which advances CMC technologies and implements digitalization strategies.

SWX:LONN Earnings and Revenue History April 11th 2025 How Do Unusual Items Influence Profit? To properly understand Lonza Group's profit results, we need to consider the CHF284m e ...

Here is how Bayer Aktiengesellschaft (BAYRY) and Lonza Group Ag (LZAGY) have performed compared to their sector so far this year.

In a report released today, Patrick Rafaisz from UBS maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price target ...

Lonza Group (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as ...

Full Year 2024 Results Key Financial Results Revenue: CHF6.57b (down 2.1% from FY 2023).

Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY stock here.